Shanxi Wanxinyuan Technology Co., Ltd. recently announced that, based on its technological accumulation in thiophene series products, the company is actively expanding into a new R&D direction for antitumor drug intermediates.
Studies have shown that thiophene derivatives demonstrate significant potential in the field of anticancer research. Drugs synthesized with thiophene as the core structure have shown good antiproliferative activity and selectivity against lung cancer cells such as A549 and NCI-H460. They can serve as targeted inhibitors of the epidermal growth factor receptor and the signaling factor NF-κB, and may be applied in the research and development of targeted anti-lung cancer drugs.
The company’s technical team stated that it will further expand the application of thiophene compounds in the field of antitumor drugs in the future, continue to extend its product line toward higher added value, and provide high-quality intermediate support for domestic innovative drug research and development.